Supply Chain

Anil Andrade, vice-president of Global Sales at ACG World, shared insights about the growth in demand in the pharma industry and efforts put forth to achieve sustainable operations.

Qualifying material suppliers is a crucial step in ensuring safe and effective drug products.

The US currently relies heavily on imports from China and other overseas nations for APIs needed to manufacture drug products of critical importance to US patients.

A new initiative will advance access to quality medicines and vaccines in Africa.

The final drug product relies on the quality and reliability of the raw materials used in its production.

The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.

The midterm report of the European Medicines Agencies Network Strategy finds that the network has strengthened and is on track to achieve its objectives.

WHO provides a look at the world’s health as the agency turns 75.

Regulators in the European Union have published the first version a list of critical medicines in the EU to avoid potential shortages.

Drug shortages across Europe are being exacerbated by increased demand, struggling supply chains, and manufacturer suspensions.

Chris Spivey, editorial director for Pharmaceutical Technology and Biopharm International, spoke with Concetto Andrea Rizza, Marketing and Communications manager, ICE Pharma, on sustainability and ICE’s green approach at CPhI Barcelona 2023.

The agency’s solidarity mechanism allows Member States to support each other when there is a shortage of a critical medicines.

The agency is warning patients and healthcare providers about pre-filled pens falsely labeled as Ozempic.

Chris Spivey, editorial director, hosts a wide ranging discussion on the COVID-19 pandemic response, future government communications, and healthcare funding for mRNA with experts Dr. Kate Broderick, Chief Innovation Officer, Maravai LifeSciences and Dr. Tom Madden, President & CEO at Acuitas Therapeutics. Highlights include supply chain modalities, ensuring a fully trained manufacturing workforce, combining delivery with gene editing innovations, epigenetic approaches to modulate gene expression moving toward the clinic. We conclude with the huge potential for RNA expression of monoclonal antibodies and protein replacement applications.

All members of the pharmaceutical supply chain must implement reliable sourcing and manufacturing strategies that balance quality and costs to ensure the uninterrupted supply of high-quality medicines to patients worldwide.

The new policy will require trading partners to supply, accept, and manage all documentation of product and ownership of prescription drugs electronically.

Excipients should be treated equally when it comes to quality management, risk assessment, and testing.

Under the exclusive agreement, Hikma will commercialize products in Rakuten Medical’s pipeline for cancer treatment in the Middle East and North Africa region.

Mapping America’s Pharmaceutical Supply (MAPS) Act aims to establish a database including key information about critical drugs so supply chain weaknesses can be identified.

The damage to the facility, which produces 8% of US injectable drug consumption, should not significantly affect the current supply.

Problems continue despite actions by regulators to better prevent and address drug shortages.

Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

Myrna Wilson, director, Global Marketing, Strategic Growth and Technical Sales, Pharmaceutical Ingredients, Univar Solutions, discusses the state of the biopharma supply chain, movements in the patent industry, and more.

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.

The event, cosponsored by FDA and USP, hosted regulators and industry leaders to discuss the challenges in strengthening the medical product supply chain.

A CPHI North America panel discussion forewarns that CDMO supply chains are potentially the biggest single risk to product resilience.

Stockpiling excess inventory is no longer enough to respond to supply chain volatility.

Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.